Cited by 394Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsDrug Solubulity and Delivery Systems

Recent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives

Akash, Muhammad Sajid Hamid, Rehman, Kanwal·2015·Journal of Controlled Release

Abstract

Most of the administered anti-cancer drugs are hydrophobic in nature and are known to have poor water solubility, short residence time, rapid clearance from the body and systemic side effects. Polymeric-based targeted particulate carrier system has shown to directly deliver the encapsulated anti-cancer drug to the desired site of action and prevent the interaction of encapsulated drug with the normal cells. Pluronic F127 (PF127) has been widely investigated for its broad-range of therodiagnostic applications in biomedical and pharmaceutical sciences, but rapid dissolution in the physiological fluids, short residence time, rapid clearance, and weak mechanical strength are the main shortcomings that are associated with PF127 and have recently been overcome by making various modifications in the structure of PF127 notably through preparation of PF127-based mixed polymeric micelles, PF127-conjugated nanoparticles and PF127-based hydrophobically modified thermogels. In this article, we have briefly discussed the recent studies that have been conducted on various anti-cancer drugs using PF127 as nano-carrier modified with other copolymers and/or conjugated with magnetic nanoparticles. The key findings of these studies demonstrated that the modified form of PF127 can significantly increase the stability of incorporated hydrophobic drugs with enhanced in vitro cytotoxicity and cellular uptake of anti-cancer drugs. Moreover, the modified form of PF127 has also shown its therapeutic potentials as therodiagnostics in various types of tumors and cancers. Hence, it can be concluded that the modified form of PF127 exhibits significant therodiagnostic effects with increased tumor-specific delivery of anti-cancer drugs having minimal toxic effects as compared to PF127 alone and/or other copolymers.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2015.04.032

Cites

235 of 235 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PF127 is approved by the U.S. Food and Drug Administration for use in biomedical areas, especially drug delivery, tissue engineering, and administration of PF127-based drug delivery systems by oral, ocular, intranasal, subcutaneous, vaginal, and rectal routes.

    “PF127 is approved by the ‘U.S. Food and Drug Administration’ (FDA) to be used in biomedical areas especially for drug delivery, tissue engineering, and the administration of the PF127-based drug delivery system, which can be oral, ocular, intranasal, subcutaneous, vaginal, and rectal [95].”
  • PF127 is a non-ionic triblock copolymer of PEO-PPO-PEO and, being a thermo-responsive synthetic polymer, can form hydrogel near body temperature.

    “Pluronic F127 (PF127) is a non-ionic triblock copolymer of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) (PEO-PPO-PEO) and, being a thremo-responsive synthetic polymer, PF127 can form the hydrogel near the body temperature [35,95].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Akash, M. S. H., & Rehman, K.
Affiliations
  • Government College University, Faisalabad (PK)
  • University of Agriculture Faisalabad (PK)
Corresponding author
  • Akash, Muhammad Sajid Hamid
  • Rehman, Kanwal
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2015-07
Volume
209
Pages
120-138
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2026010448
Cited by
394
References
235
Citations by year
2026: 31 · 2025: 51 · 2024: 43 · 2023: 45 · 2022: 30 · 2021: 44 · 2020: 45 · 2019: 26 · 2018: 34 · 2017: 25 · 2016: 17 · 2015: 3
FWCI
1.59
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Keywords
Pluronic F127, polymeric micelles, anticancer drug delivery, hydrophobic drug solubilization, theranostics, tumor-specific drug delivery, cellular uptake, drug stability, thermosensitive hydrogel, copolymers
MeSH terms
Animals, Antineoplastic Agents, Drug Carriers, Gels, Humans, Micelles, Poloxamer, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review